World Health Organization Issues Alert Over Severe Scarcity of Obesity Jabs
Under one in 10 individuals eligible to benefit from obesity jabs like Wegovy can access them, caution the global health agency as it publishes its inaugural advice on the therapies.
Considering over a billion individuals worldwide now obese, it is calling for broader and more equitable access to GLP-1 medication.
Per projections, over two billion could be obese by 2030 if no action is taken.
"The latest guidance affirms that obesity is a chronic disease that can be managed with comprehensive and continuous support," stated WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and distribution challenges are major hurdles to broad availability to the injections that can aid individuals in losing significant weight, explains the organization.
Skinny Jab Supply Crisis
Even under the present most optimistic scenario, the manufacturing of GLP-1 therapies might only reach approximately 100 million people – fewer than 10% of the global need, according to the health organization.
The advice encourages countries and companies to widen access, through strategies like voluntary licensing.
The intellectual property rights on the active ingredient – the primary component of a leading brand – is set to lapse in several nations in 2026.
The Way Obesity Injections Work
GLP-1 drugs imitate a biological compound to delay gastric emptying, suppress the appetite and increase the sense of being full so users eat less.
Individuals usually begin shedding pounds in the initial weeks of commencing the weekly injections.
Evidence points to users may regain a significant portion a year later of halting the drug, when their normal appetite return.
Being carrying excess weight increases your likelihood for contracting medical conditions, including diabetes, heart disease, stroke, and specific malignancies.
Excess weight concerns individuals in countries worldwide and was associated with over three and a half million fatalities worldwide in 2024, as per the health agency.
